InvestorsHub Logo
Followers 144
Posts 27604
Boards Moderated 3
Alias Born 02/07/2004

Re: midastouch017 post# 2573

Tuesday, 12/22/2020 11:31:27 AM

Tuesday, December 22, 2020 11:31:27 AM

Post# of 3894
Late-stage study with RedHill Biopharma's COVID-19 candidate to continue unchanged
Dec. 22, 2020 11:27 AM ETRedHill Biopharma Ltd. (RDHL)

By: Aakash Babu, SA News Editor

Following a second independent Data Safety Monitoring Board (DSMB) safety review, RedHill Biopharma (RDHL +0.1%) has received a second unanimous recommendation to continue its global Phase 2/3 study testing Opaganib in hospitalized patients with severe COVID-19 pneumonia.

The recommend ation is based on an analysis of unblinded safety data from the first 155 patients treated for 14 days. Top-line data from the 270-patient study is expected Q1 in 2021.

In parallel, the company is conducting an additional U.S. Phase 2 study with opaganib in COVID-19. The trial has completed enrollment of all 40 patients and data is expected shortly.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News